As pointed out earlier, in copies per cell EpCAM can probably not compete with Her2/Neu in the subpopulation of Her2 positive breast cancers, but in percentage of positive breast tumours EpCAM is clearly the more prevalent target. The gene discussed is EPCAM; the disease is breast neoplasm.